Patents by Inventor Gordon J. Freeman

Gordon J. Freeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
    Patent number: 10934353
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 2, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS
    Publication number: 20210032334
    Abstract: The present invention relates, in part, to methods of treating cancers using combinations of anti-BTNL2 and anti-immune checkpoint therapies.
    Type: Application
    Filed: February 27, 2019
    Publication date: February 4, 2021
    Inventors: Gordon J. Freeman, Yanping Xiao
  • HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
    Publication number: 20200172616
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: July 9, 2019
    Publication date: June 4, 2020
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • ANTI-PHOSPHOTYROSINYLATED PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20200115452
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 16, 2020
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Straus
  • AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20200095325
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Application
    Filed: September 16, 2019
    Publication date: March 26, 2020
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF MELANOMA USING PD-L1 ISOFORMS
    Publication number: 20190375818
    Abstract: The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.
    Type: Application
    Filed: March 27, 2019
    Publication date: December 12, 2019
    Inventors: F. Stephen Hodi, Jun Zhou, Gordon J. Freeman, Jingjing Li, Xinqi Wu
  • ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20190330350
    Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of PD-L1 antibodies useful for diagnostic, prognostic, and therapeutic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.
    Type: Application
    Filed: December 10, 2018
    Publication date: October 31, 2019
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Agents that modulate immune cell activation and methods of use thereof
    Patent number: 10457733
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • METHODS FOR TREATING PTEN DEFICIENT EPITHELIAL CANCERS USING A COMBINATION OF ANTI-PI3KBETA AND ANTI-IMMUNE CHECKPOINT AGENTS
    Publication number: 20190298728
    Abstract: The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 3, 2019
    Inventors: Jean Zhao, Johann Bergholz, Gordon J. Freeman, Thomas M. Roberts
  • Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
    Patent number: 10370448
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 6, 2019
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Anti-PD-L1 monoclonal antibodies and fragments thereof
    Patent number: 10202454
    Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of PD-L1 antibodies useful for diagnostic, prognostic, and therapeutic applications, as well as immunoglobulins polypeptides, and nucleic acids thereof.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 12, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
    Publication number: 20180371084
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 27, 2018
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • METHODS OF REDUCING LIVER PD-1-EXPRESSING CD8+ T CELLS USING PD-1 FC FUSION PROTEINS THAT BIND FC RECEPTORS
    Publication number: 20180355039
    Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.
    Type: Application
    Filed: September 16, 2016
    Publication date: December 13, 2018
    Inventors: Gordon J. Freeman, Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin
  • REGULATORY T CELL PD-1 MODULATION FOR REGULATING T CELL EFFECTOR IMMUNE RESPONSES
    Publication number: 20180303922
    Abstract: The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Inventors: Arlene H. Sharpe, Gordon J. Freeman, Loise M. Francisco, Peter T. Sage, Sun J. Lee, Scott B. Lovitch, Vikram R. Juneja, Catherine L. Tan
  • METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS
    Publication number: 20180271977
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 27, 2018
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
  • PD-L2 BIOMARKERS PREDICTIVE OF PD-1 PATHWAY INHIBITOR RESPONSES IN ESOPHAGOGASTRIC CANCERS
    Publication number: 20180238884
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness of esophagogastric cancers to inhibitors of the PD-1 pathway.
    Type: Application
    Filed: March 3, 2016
    Publication date: August 23, 2018
    Inventors: Adam Bass, Sarah Derks, Gordon J. Freeman, Scott J. Rodig
  • SINGLE AGENT ANTI-PD-L1 AND PD-L2 DUAL BINDING ANTIBODIES AND METHODS OF USE
    Publication number: 20180201680
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
    Type: Application
    Filed: November 7, 2017
    Publication date: July 19, 2018
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
    Patent number: 10011656
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 3, 2018
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Methods related to TIM 3, a TH1-specific cell surface molecule, for activating antigen presenting cells
    Patent number: 9962440
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: May 8, 2018
    Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Vijay K. Kuchroo, Sumone Chakravarti, Catherine A. Sabatos-Peyton, Gordon J. Freeman
  • METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS
    Publication number: 20180002422
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Application
    Filed: December 7, 2015
    Publication date: January 4, 2018
    Inventors: Gordon J. Freeman, Yanping Xiao